Bio Pharma Dive
AUGUST 2, 2024
The one-time drug developer is pivoting to cancer research. Elsewhere, Neurocrine reported a strong quarter and venBio raised half a billion dollars for biotech investing.
Pharmaceutical Technology
AUGUST 2, 2024
AbbVie has completed its acquisition of all outstanding shares of Cerevel Therapeutics in a deal valued at $8.7bn.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Bio Pharma Dive
AUGUST 2, 2024
Adaptimmune’s Tecelra is the first TCR cell therapy to reach market and, at $727,000, is also the priciest cellular medicine for cancer in the U.S.
Pharmaceutical Technology
AUGUST 2, 2024
The MAGE-A4-targeted genetically modified T cell therapy is indicated for the treatment of synovial sarcoma.
Speaker: Simran Kaur, Co-founder & CEO at Tattva Health Inc.
AI is transforming clinical trials—accelerating drug discovery, optimizing patient recruitment, and improving data analysis. But its impact goes far beyond research. As AI-driven innovation reshapes the clinical trial process, it’s also influencing broader healthcare trends, from personalized medicine to patient outcomes. Join this new webinar featuring Simran Kaur for an insightful discussion on what all of this means for the future of healthcare!
Bio Pharma Dive
AUGUST 2, 2024
A special committee of the board said the proposal offers no premium to 23andMe’s stock price and, with a lack of committed financing, is “insufficient.
Pharmaceutical Technology
AUGUST 2, 2024
Merck KGaA has concluded the acquisition of Mirus Bio for €500m ($600m), enhancing its viral vector bioprocessing capabilities.
Clinical Research Informer brings together the best content for clinical researchers from the widest variety of industry thought leaders.
Fierce Pharma
AUGUST 2, 2024
Adaptimmune has won accelerated FDA approval | Adaptimmune has won accelerated FDA approval for Tecelra (afami-cel), a treatment for metastatic or unresectable synovial sarcoma which becomes the first engineered cell therapy for a solid tumor and the first new treatment in the indication in more than a decade.
Pharma Times
AUGUST 2, 2024
The third leading cause of cancer mortality accounts for over 700,000 deaths every year
Pharmaceutical Technology
AUGUST 2, 2024
In 2023, Casgevy was approved in the US to treat sickle cell disease (SCD), making it the first FDA-approved gene therapy to use CRISPR-based gene editing.
pharmaphorum
AUGUST 2, 2024
Eli Lilly's dual GLP-1/GIP agonist tirzepatide has been shown to reduce the risk of worsening disease in people with heart failure and obesity in a phase 3 trial, the first to show a benefit on cardiovascular outcomes with the drug.
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
Pharmaceutical Technology
AUGUST 2, 2024
The company has fired 25% of staff and discontinued pipeline programs to funnel funds into developing candidates licenced from Sanofi.
Fierce Pharma
AUGUST 2, 2024
As growth in Vertex's cystic fibrosis portfolio buoys the company amid the launch of gene therapy Casgevy, the company is feeling confident enough to boost its revenue outlook for the year. | As of mid-July, around 20 patients completed the first step of Casgevy treatment by having their cells collected, up from five patients during the first quarter.
Pharmaceutical Technology
AUGUST 2, 2024
Alemtuzumab, under the brand name Campath, was pulled from the leukaemia market by Sanofi in 2012.
pharmaphorum
AUGUST 2, 2024
Discover how artificial intelligence is revolutionising the pharmaceutical industry and how it can potentially save time, resources, and lives. Learn more about the impact of AI on pharma and discussions at PING 2024.
Pharmaceutical Technology
AUGUST 2, 2024
GSK announced that Jemperli plus chemotherapy has obtained expanded FDA approval for primary advanced or recurrent endometrial cancer.
pharmaphorum
AUGUST 2, 2024
Discover how digital transformation is reshaping the pharmaceutical industry and learn how to prepare your workforce for the future with this guide on building a future-ready digital workforce in pharma.
Pharmaceutical Technology
AUGUST 2, 2024
Sanofi has announced a significant investment of €1.3bn ($1.4bn) to expand its insulin production capabilities in Frankfurt, Germany.
pharmaphorum
AUGUST 2, 2024
Explore the latest mergers, acquisitions, and partnerships in June 2024 involving LucidHealth, Syncona, Spur Therapeutics and more. Stay updated on the business collaborations shaping the industry.
Advertisement
White paper that delves into the complex topic of Decentralized Clinical Trials and how to master them within the confines of FDA Regulations
Pharmaceutical Technology
AUGUST 2, 2024
Rejuvenate and SAS will create a tool to simplify the drug development process, used to repurpose drugs for age-related diseases.
Pharmaceutical Commerce
AUGUST 2, 2024
In deal that has the potential to reach $1.1 billion, Otsuka aims to grow its drug pipeline, specifically in the field of rare and autoimmune diseases.
pharmaphorum
AUGUST 2, 2024
FDA has approved Adaptimmune's Tecelra for synovial sarcoma, the first engineered T-cell therapy for solid tumours
Pharmaceutical Commerce
AUGUST 2, 2024
The latest news for pharma industry insiders.
pharmaphorum
AUGUST 2, 2024
FDA clears GSK's Jemperli as first-line therapy for all endometrial cancer patients, seen as key to driving sales above the $1bn threshold
Outsourcing Pharma
AUGUST 2, 2024
Rejuvenate Biomed and SAS have announced a creative partnership aimed at making big changes to drug discovery through the development of a user-friendly, AI-powered tool.
Fierce Pharma
AUGUST 2, 2024
Merck is trying to determine the reasons behind the surprise decline of Gardasil in China. Eisai and Biogen's Leqembi was rejected by European authorities amid a continued slow sales ramp. | Merck is trying to determine the reasons behind the surprise decline of Gardasil in China. Eisai and Biogen's Leqembi was rejected by European authorities amid a continued slow sales ramp.
Outsourcing Pharma
AUGUST 2, 2024
As the BioSecure Act approaches its 2032 implementation, Contract Development and Manufacturing Organizations (CDMOs) must prepare for significant industry shifts.
Advertisement
This new white paper defines and details the impact of Decentralized Clinical Trials on the Pharmaceutical industry and how the impact can be measured along with steps companies can take to ensure adoption.
Fierce Pharma
AUGUST 2, 2024
This week on “The Top Line,” we discuss two studies in HIV research that were presented at the 25th International AIDS | This week on “The Top Line,” we dive into two studies in HIV research that were presented at the 25th International AIDS Conference in Germany.
pharmaphorum
AUGUST 2, 2024
Sonde Health has made a name for itself with the development of software that can detect illness from the sound of a patient's voice. Now, it has launched a dedicated app for tracking cognitive fitness, which it hopes may be able to spot signs of decline early.The app – Sonde Cognitive Fitness – allows users to monitor brain exertion in real-time by analysing vocal biomarkers using machine learning, an approach that is analogous to the use of fitness trackers to monitor physical and heart health
Drug Patent Watch
AUGUST 2, 2024
This chart shows the drugs with the most patents in Ireland. Patents must be filed in each country (or, in some cases regional patent office) where patent protection is desired.
Cloudbyz
AUGUST 2, 2024
Informed consent is one of the cornerstones of ethical clinical research. We would not be able to advance medicine without consenting participants and patients. The informed consent process educates potential participants about the key elements of a clinical trial before they decide whether to participate. This process ensures that participants are fully aware of the risks, benefits, and their rights within the study.
Advertisement
Planning on running clinical trials in Japan? How can you reliably supply these studies? Discover Catalent’s clinical supply packaging facility in Shiga, Japan. Strategically located between Tokyo and Osaka, and one of largest in Japan, this 6,000 square meter facility offers comprehensive services including primary and secondary clinical packaging and labelling, comparator sourcing, cold chain storage, local and global distribution, local language support and white glove service to support stud
Expert insights. Personalized for you.
176 
Let's personalize your content